Code,Country,Study,Submission,Documents,Note,Date
AE,United Arab Emirates,Pre-Market,CA,Cover Letter on headed paper,Addressed by Principal Investigator to Dubai Scientific research Ethics Committee),2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Application form,Download from webpage,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CIP & all curents admendments,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Synopsis ,in EN,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CRF,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,IB,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,PI have to obtain HOD signature,If multicenter study,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Approval from Head of Department and CEO of hospital,If study is conduct in Dubai Hospitals. contact Dubai Hospital Professional Development Office DHPDO@dha.gov.ae to know more.,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Approval is required to be obtained from Director of Primary health Care Centers,If Study is conducting at DHA Primary health Care Centers. Contact PHCC Professional Development Office.,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CIP,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Synopsis,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Patient Information and Informed Consent,EN & ARABIC. Template available ,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,All Data collection Forms,"Patient diary, cards, questionnaires â€¦",2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Budget plan,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Financial Disclosure of Principal Investigator.,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Agreements between parties,to be digned by the PI,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,"PI CV, GCP",,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Proof of insurance ,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CE-mark certification,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Payment ,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,If non-interventional trial. ,EC submission & evaluation. CA notification only,2022-07-03
AE,United Arab Emirates,Post-Market,CA,"If interventional, same as in pre-market",,2022-07-03
AU,Australia,Pre-Market,CA,The application Part 1,Download from web,2022-07-03
AU,Australia,Pre-Market,CA,Application fee,https://www.tga.gov.au/fees-and-charges-summary-1-december-2021,2022-07-03
AU,Australia,Pre-Market,CA,Sponsor statement,,2022-07-03
AU,Australia,Pre-Market,CA,Section 3: Medical devices details,"description of the device; details of design, composition, specification, mode of action and application; and method of use.",2022-07-03
AU,Australia,Pre-Market,CA,Instruction for sending part 1,The CTA application form can be emailed to us. Supporting data for the CTA application should be provided in electronic format. It is preferable for data to be sent on USB or CD-ROM via post.,2022-07-03
AU,Australia,Pre-Market,CA,The application Part 2,Download from web,2022-07-03
AU,Australia,Pre-Market,CA,1.5 Site sustainability,Completed by the sponsor,2022-07-03
AU,Australia,Pre-Market,CA,1.6 Sponsor certification,Completed by the sponsor,2022-07-03
AU,Australia,Pre-Market,CA,section 2,Completed by the sponsor,2022-07-03
AU,Australia,Pre-Market,CA,Instruction for sending part 2,This form must be sent to the Therapeutic Goods Administration within 28 days of commencing supply of the goods. Send to: The Medical Advisor Experimental Drugs Section Office of Scientific Evaluation Therapeutic Goods Administration PO Box 100 Woden ACT 2606 Australia,2022-07-03
AU,Australia,Post-Market,CA,The application Part 1,Download from web,2022-07-03
AU,Australia,Post-Market,CA,Application fee,https://www.tga.gov.au/fees-and-charges-summary-1-december-2021,2022-07-03
AU,Australia,Post-Market,CA,Sponsor statement,,2022-07-03
AU,Australia,Post-Market,CA,Section 3: Medical devices details,"description of the device; details of design, composition, specification, mode of action and application; and method of use.",2022-07-03
AU,Australia,Post-Market,CA,Instruction for sending part 1,The CTA application form can be emailed to us. Supporting data for the CTA application should be provided in electronic format. It is preferable for data to be sent on USB or CD-ROM via post.,2022-07-03
AU,Australia,Post-Market,CA,The application Part 2,Download from web,2022-07-03
AU,Australia,Post-Market,CA,1.5 Site sustainability,Completed by the sponsor,2022-07-03
AU,Australia,Post-Market,CA,1.6 Sponsor certification,Completed by the sponsor,2022-07-03
AU,Australia,Post-Market,CA,section 2,Completed by the sponsor,2022-07-03
AU,Australia,Post-Market,CA,Instruction for sending part 2,This form must be sent to the Therapeutic Goods Administration within 28 days of commencing supply of the goods. Send to: The Medical Advisor Experimental Drugs Section Office of Scientific Evaluation Therapeutic Goods Administration PO Box 100 Woden ACT 2606 Australia,2022-07-03
CN,China,Pre-Market,CA,CIP,Appendix 2 sfda regulation,2022-07-03
CN,China,Pre-Market,CA,Patient information and ICF,,2022-07-03
CN,China,Pre-Market,CA,Technical documents of the product,,2022-07-03
CN,China,Pre-Market,CA,Risk analysis,,2022-07-03
CN,China,Pre-Market,CA,GDPR,,2022-07-03
CN,China,Pre-Market,CA,"PI CV, GCP",,2022-07-03
CN,China,Post-Market,CA,CIP,Appendix 2 sfda regulation,2022-07-03
CN,China,Post-Market,CA,Patient information and ICF,,2022-07-03
CN,China,Post-Market,CA,Technical documents of the product,,2022-07-03
CN,China,Post-Market,CA,Risk analysis,,2022-07-03
CN,China,Post-Market,CA,GDPR,,2022-07-03
CN,China,Post-Market,CA,"PI CV, GCP",,2022-07-03
ID,Indonesia,Pre-Market,CA,Clinical trial protocol,,2022-07-03
ID,Indonesia,Pre-Market,CA,Patient information and ICF,,2022-07-03
ID,Indonesia,Pre-Market,CA,EC Approval,,2022-07-03
ID,Indonesia,Pre-Market,CA,IB,,2022-07-03
ID,Indonesia,Pre-Market,CA,Device information ,,2022-07-03
ID,Indonesia,Pre-Market,CA,"PI Cvs, GCPs",,2022-07-03
ID,Indonesia,Pre-Market,CA,Contract,,2022-07-03
ID,Indonesia,Pre-Market,CA,Proof of insurance,,2022-07-03
ID,Indonesia,Pre-Market,CA,IFU,,2022-07-03
ID,Indonesia,Post-Market,CA,Clinical trial protocol,,2022-07-03
ID,Indonesia,Post-Market,CA,Patient information and ICF,,2022-07-03
ID,Indonesia,Post-Market,CA,EC Approval,,2022-07-03
ID,Indonesia,Post-Market,CA,IB,,2022-07-03
ID,Indonesia,Post-Market,CA,Device information ,,2022-07-03
ID,Indonesia,Post-Market,CA,"PI Cvs, GCPs",,2022-07-03
ID,Indonesia,Post-Market,CA,Contract,,2022-07-03
ID,Indonesia,Post-Market,CA,Proof of insurance,,2022-07-03
ID,Indonesia,Post-Market,CA,IFU,,2022-07-03
IN,India,Pre-Market,CA,Cover Letter,"Indicate sponsor, PI",2022-07-03
IN,India,Pre-Market,CA,Authorization letter from Sponsor,,2022-07-03
IN,India,Pre-Market,CA,Application form,,2022-07-03
IN,India,Pre-Market,CA,CIP,,2022-07-03
IN,India,Pre-Market,CA,Synopsis,,2022-07-03
IN,India,Pre-Market,CA,IB,,2022-07-03
IN,India,Pre-Market,CA,Patient information And ICF,,2022-07-03
IN,India,Pre-Market,CA,Name of participating countries & their CA,For study outside India. Copy of CA approval if available,2022-07-03
IN,India,Pre-Market,CA,declaring that the study has not been discontinued in any country.,For study outside India,2022-07-03
IN,India,Pre-Market,CA,Other EC approval ,If applicable,2022-07-03
IN,India,Pre-Market,CA,GDPR,,2022-07-03
IN,India,Pre-Market,CA,CRF template,,2022-07-03
IN,India,Pre-Market,CA,"PI CV, GCP",,2022-07-03
IN,India,Pre-Market,CA,Proof of insurance,,2022-07-03
IN,India,Pre-Market,CA,Risk & benefits assessment,,2022-07-03
In,Unknown,Post-Market,CA,Cover Letter,"Indicate sponsor, PI",2022-07-03
In,Unknown,Post-Market,CA,Authorization letter from Sponsor,,2022-07-03
In,Unknown,Post-Market,CA,Application form,,2022-07-03
In,Unknown,Post-Market,CA,CIP,,2022-07-03
In,Unknown,Post-Market,CA,Synopsis,,2022-07-03
In,Unknown,Post-Market,CA,IB,,2022-07-03
In,Unknown,Post-Market,CA,Patient information And ICF,,2022-07-03
In,Unknown,Post-Market,CA,Name of participating countries & their CA,For study outside India. Copy of CA approval if available,2022-07-03
In,Unknown,Post-Market,CA,declaring that the study has not been discontinued in any country.,For study outside India,2022-07-03
In,Unknown,Post-Market,CA,Other EC approval ,If applicable,2022-07-03
In,Unknown,Post-Market,CA,GDPR,,2022-07-03
In,Unknown,Post-Market,CA,CRF template,,2022-07-03
In,Unknown,Post-Market,CA,"PI CV, GCP",,2022-07-03
In,Unknown,Post-Market,CA,Proof of insurance,,2022-07-03
In,Unknown,Post-Market,CA,Risk & benefits assessment,,2022-07-03
In,Unknown,Post-Market,CA,CE mark certificate,For PMCF,2022-07-03
In,Unknown,Post-Market,CA,"Summary of phase I, II, III",For PMCF,2022-07-03
JP,Japan,Pre-Market,CA,1.1 Standard business procedure manual,,2022-07-03
JP,Japan,Pre-Market,CA,"1.2 ""Procedures specific to the clinical trial""",,2022-07-03
JP,Japan,Pre-Market,CA,"2.1 Clinical trial implementation system; 2.2 Medical specialists; 2.3 ""Clinical trial coordinator and
Clinical Trial Coordination Committee
(if it applies)""; 2.4 ""Development contract research organization, etc. (if it applies)""",,2022-07-03
JP,Japan,Pre-Market,CA,3.1 CIP,,2022-07-03
JP,Japan,Pre-Market,CA,3.2 CRF,,2022-07-03
JP,Japan,Pre-Market,CA,4.1 Clinical trial equipment summary,,2022-07-03
JP,Japan,Pre-Market,CA,5.1 Patient information & ICF,,2022-07-03
JP,Japan,Pre-Market,CA,5.2 Compensation (if applicable),,2022-07-03
JP,Japan,Pre-Market,CA,6. Notification documents,AE reports,2022-07-03
JP,Japan,Pre-Market,CA,7. Documents on compensation measures for health damage,,2022-07-03
JP,Japan,Pre-Market,CA,8. Management of clinical trial equipment,,2022-07-03
JP,Japan,Pre-Market,CA,9. Records regarding the Effectiveness and Safety Evaluation Committee (if applicable),,2022-07-03
JP,Japan,Pre-Market,CA,10 Data management,,2022-07-03
JP,Japan,Pre-Market,CA,11 Statistical analysis,,2022-07-03
JP,Japan,Pre-Market,CA,12. Summary report,,2022-07-03
JP,Japan,Pre-Market,CA,13.1 Selection record,,2022-07-03
JP,Japan,Pre-Market,CA,"13.2 Resume of investigator, etc.",,2022-07-03
JP,Japan,Pre-Market,CA,"13.3 ""List of investigators and collaborators""",,2022-07-03
JP,Japan,Pre-Market,CA,13.4 Signature / Imprint List,,2022-07-03
JP,Japan,Pre-Market,CA,13.5 Agreement document,,2022-07-03
JP,Japan,Pre-Market,CA,13.6 Consent Explanatory Document,,2022-07-03
JP,Japan,Pre-Market,CA,13.7 Clinical Trial Request Form,,2022-07-03
JP,Japan,Pre-Market,CA,13.8 IRB Approval Document,,2022-07-03
JP,Japan,Pre-Market,CA,13.9 Change application,,2022-07-03
JP,Japan,Pre-Market,CA,13.10 Contract,,2022-07-03
JP,Japan,Pre-Market,CA,"13.11 ""Storage and management records of clinical trial equipment (copy)""",,2022-07-03
JP,Japan,Pre-Market,CA,"13.12 ""Clinical Trial Equipment Delivery and Handling Record""",,2022-07-03
JP,Japan,Pre-Market,CA,13.13 Case report,,2022-07-03
JP,Japan,Pre-Market,CA,"13.14 ""Serious adverse events and",,2022-07-03
JP,Japan,Pre-Market,CA,"Report on bugs """,,2022-07-03
JP,Japan,Pre-Market,CA,"13.15 ""Record of deviation from clinical trial protocol""",,2022-07-03
JP,Japan,Pre-Market,CA,"13.16 ""Safety Notice / Report Document""",,2022-07-03
JP,Japan,Pre-Market,CA,"13.17 ""Clinical Trial Completion Notification Document from the Director of the Conducting Medical Institution""",,2022-07-03
JP,Japan,Pre-Market,CA,13.18 Monitoring Report,,2022-07-03
JP,Japan,Pre-Market,CA,"13.19 ""Records that guarantee quality control, etc. at inspection agencies (if applicable)""",,2022-07-03
JP,Japan,Pre-Market,CA,14. Audit plan ,,2022-07-03
JP,Japan,Post-Market,CA,1.1 Standard business procedure manual,,2022-07-03
JP,Japan,Post-Market,CA,"1.2 ""Procedures specific to the clinical trial""",,2022-07-03
JP,Japan,Post-Market,CA,"2.1 Clinical trial implementation system; 2.2 Medical specialists; 2.3 ""Clinical trial coordinator and
Clinical Trial Coordination Committee
(if it applies)""; 2.4 ""Development contract research organization, etc. (if it applies)""",,2022-07-03
JP,Japan,Post-Market,CA,3.1 CIP,,2022-07-03
JP,Japan,Post-Market,CA,3.2 CRF,,2022-07-03
JP,Japan,Post-Market,CA,4.1 Clinical trial equipment summary,,2022-07-03
JP,Japan,Post-Market,CA,5.1 Patient information & ICF,,2022-07-03
JP,Japan,Post-Market,CA,5.2 Compensation (if applicable),,2022-07-03
JP,Japan,Post-Market,CA,6. Notification documents,AE reports,2022-07-03
JP,Japan,Post-Market,CA,7. Documents on compensation measures for health damage,,2022-07-03
JP,Japan,Post-Market,CA,8. Management of clinical trial equipment,,2022-07-03
JP,Japan,Post-Market,CA,9. Records regarding the Effectiveness and Safety Evaluation Committee (if applicable),,2022-07-03
JP,Japan,Post-Market,CA,10 Data management,,2022-07-03
JP,Japan,Post-Market,CA,11 Statistical analysis,,2022-07-03
JP,Japan,Post-Market,CA,12. Summary report,,2022-07-03
JP,Japan,Post-Market,CA,13.1 Selection record,,2022-07-03
JP,Japan,Post-Market,CA,"13.2 Resume of investigator, etc.",,2022-07-03
JP,Japan,Post-Market,CA,"13.3 ""List of investigators and collaborators""",,2022-07-03
JP,Japan,Post-Market,CA,13.4 Signature / Imprint List,,2022-07-03
JP,Japan,Post-Market,CA,13.5 Agreement document,,2022-07-03
JP,Japan,Post-Market,CA,13.6 Consent Explanatory Document,,2022-07-03
JP,Japan,Post-Market,CA,13.7 Clinical Trial Request Form,,2022-07-03
JP,Japan,Post-Market,CA,13.8 IRB Approval Document,,2022-07-03
JP,Japan,Post-Market,CA,13.9 Change application,,2022-07-03
JP,Japan,Post-Market,CA,13.10 Contract,,2022-07-03
JP,Japan,Post-Market,CA,"13.11 ""Storage and management records of clinical trial equipment (copy)""",,2022-07-03
JP,Japan,Post-Market,CA,"13.12 ""Clinical Trial Equipment Delivery and Handling Record""",,2022-07-03
JP,Japan,Post-Market,CA,13.13 Case report,,2022-07-03
JP,Japan,Post-Market,CA,"13.14 ""Serious adverse events and",,2022-07-03
JP,Japan,Post-Market,CA,"Report on bugs """,,2022-07-03
JP,Japan,Post-Market,CA,"13.15 ""Record of deviation from clinical trial protocol""",,2022-07-03
JP,Japan,Post-Market,CA,"13.16 ""Safety Notice / Report Document""",,2022-07-03
JP,Japan,Post-Market,CA,"13.17 ""Clinical Trial Completion Notification Document from the Director of the Conducting Medical Institution""",,2022-07-03
JP,Japan,Post-Market,CA,13.18 Monitoring Report,,2022-07-03
JP,Japan,Post-Market,CA,"13.19 ""Records that guarantee quality control, etc. at inspection agencies (if applicable)""",,2022-07-03
JP,Japan,Post-Market,CA,14. Audit plan ,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Cover Letter,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,CIP,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,IB,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Patient information and ICF,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Information on the finance,Contracts,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Compensation to subjects,If applicable,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Proof of insurance,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,EC Approval ,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,"PI CV, GCP",,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Normal lab ranges,If applicable,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Sample of labeling,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Cover Letter,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,CIP,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,IB,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Patient information and ICF,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Information on the finance,Contracts,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Compensation to subjects,If applicable,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Proof of insurance,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,EC Approval ,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,"PI CV, GCP",,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Normal lab ranges,If applicable,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Sample of labeling,,2022-07-03
MY,Malaysia,Pre-Market,CA,Application Form,From the guidance document,2022-07-03
MY,Malaysia,Pre-Market,CA,CIP ,,2022-07-03
MY,Malaysia,Pre-Market,CA,ICF ,,2022-07-03
MY,Malaysia,Pre-Market,CA,Sample of device packaging label,,2022-07-03
MY,Malaysia,Pre-Market,CA,EC approval Letter,,2022-07-03
MY,Malaysia,Post-Market,CA,Application Form,From the guidance document,2022-07-03
MY,Malaysia,Post-Market,CA,CIP ,,2022-07-03
MY,Malaysia,Post-Market,CA,ICF ,,2022-07-03
MY,Malaysia,Post-Market,CA,Sample of device packaging label,,2022-07-03
MY,Malaysia,Post-Market,CA,EC approval Letter,,2022-07-03
NZ,New Zealand,Pre-Market,CA,"PI Cvs, GCPs. All teams",,2022-07-03
NZ,New Zealand,Pre-Market,CA,GMP certification for manufacturer,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Signed ICF,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Protocols,Signed and Dated,2022-07-03
NZ,New Zealand,Pre-Market,CA,IB,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Labelling sample,,2022-07-03
NZ,New Zealand,Post-Market,CA,"PI Cvs, GCPs. All teams",,2022-07-03
NZ,New Zealand,Post-Market,CA,GMP certification for manufacturer,,2022-07-03
NZ,New Zealand,Post-Market,CA,Signed ICF,,2022-07-03
NZ,New Zealand,Post-Market,CA,Protocols,Signed and Dated,2022-07-03
NZ,New Zealand,Post-Market,CA,IB,,2022-07-03
NZ,New Zealand,Post-Market,CA,Labelling sample,,2022-07-03
PH,Philippines,Pre-Market,CA,Application Form,Annex G or H of the document,2022-07-03
PH,Philippines,Pre-Market,CA,Proof of payment,,2022-07-03
PH,Philippines,Pre-Market,CA,Copy of Letter of authorization,,2022-07-03
PH,Philippines,Pre-Market,CA,"A government - issued certificate attesting to the status of the Manufacturer with regard to the competence and reliability of the personnel and facilities,",,2022-07-03
PH,Philippines,Pre-Market,CA,Certificate of Product Registration,For imported product,2022-07-03
PH,Philippines,Pre-Market,CA,Colored picture of the device from all sides,,2022-07-03
PH,Philippines,Pre-Market,CA,Device description,All class of MD,2022-07-03
PH,Philippines,Pre-Market,CA,CE marking ,(if applicable),2022-07-03
PH,Philippines,Pre-Market,CA,Labelling example,All class of MD,2022-07-03
PH,Philippines,Pre-Market,CA,Executive summary,"Class B, C, D",2022-07-03
PH,Philippines,Pre-Market,CA,"Relevant essential principles and method/s used to demonstrate conformity,",If applicable. Annex K,2022-07-03
PH,Philippines,Pre-Market,CA,Summary ofDesign Verification and Validation Documents:,"Class B, C, D",2022-07-03
PH,Philippines,Pre-Market,CA,Risk analysis,"Class B, C, D",2022-07-03
PH,Philippines,Pre-Market,CA,Physical Manufacturer information,"Class B, C, D",2022-07-03
PH,Philippines,Post-Market,CA,Application Form,Annex G or H of the document,2022-07-03
PH,Philippines,Post-Market,CA,Proof of payment,,2022-07-03
PH,Philippines,Post-Market,CA,Copy of Letter of authorization,,2022-07-03
PH,Philippines,Post-Market,CA,"A government - issued certificate attesting to the status of the Manufacturer with regard to the competence and reliability of the personnel and facilities,",,2022-07-03
PH,Philippines,Post-Market,CA,Certificate of Product Registration,For imported product,2022-07-03
PH,Philippines,Post-Market,CA,Colored picture of the device from all sides,,2022-07-03
PH,Philippines,Post-Market,CA,Device description,All class of MD,2022-07-03
PH,Philippines,Post-Market,CA,CE marking ,(if applicable),2022-07-03
PH,Philippines,Post-Market,CA,Labelling example,All class of MD,2022-07-03
PH,Philippines,Post-Market,CA,Executive summary,"Class B, C, D",2022-07-03
PH,Philippines,Post-Market,CA,"Relevant essential principles and method/s used to demonstrate conformity,",If applicable. Annex K,2022-07-03
PH,Philippines,Post-Market,CA,Summary ofDesign Verification and Validation Documents:,"Class B, C, D",2022-07-03
PH,Philippines,Post-Market,CA,Risk analysis,"Class B, C, D",2022-07-03
PH,Philippines,Post-Market,CA,Physical Manufacturer information,"Class B, C, D",2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Application form,See Annex (1-A)/(1-B),2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Labelling of Medical device,Device is intended to be used exclusively for conducting the clinical trial.,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,rf,Signed & dated,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Agreements between sponsor vs CRO,Signed & dated,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Local EC approval letter,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,CIP,Lastest version approved by EC,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,IB,Pre-market only,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Patient information & ICF,In Arabic & English,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Proof of insurance,Only for interventional study,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,PI CV & GCP,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Disclosure of Principal Investigator Conflict of Interests,Signed by the PI,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Authorized representative (AR) licence,It is only required for sponsors located outside KSA.,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,CRO establishment licence,If the CRO is contracted by sponsor,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Application form,See Annex (1-A)/(1-B),2022-07-03
SA,Saudi Arabia,Post-Market,CA,Labelling of Medical device,Device is intended to be used exclusively for conducting the clinical trial.,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Agreements between sponsor vs PI/site,Signed & dated,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Agreements between sponsor vs CRO,Signed & dated,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Local EC approval letter,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,CIP,Lastest version approved by EC,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Patient information & ICF,In Arabic & English,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Proof of insurance,Only for interventional study,2022-07-03
SA,Saudi Arabia,Post-Market,CA,PI CV & GCP,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Disclosure of Principal Investigator Conflict of Interests,Signed by the PI,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Authorized representative (AR) licence,It is only required for sponsors located outside KSA.,2022-07-03
SA,Saudi Arabia,Post-Market,CA,CRO establishment licence,If the CRO is contracted by sponsor,2022-07-03
TH,Thailand,Pre-Market,CA,Cover Letter ,,2022-07-03
TH,Thailand,Pre-Market,CA,Checklists and Attached Documents for Application Import License of the product. ,Document name: Nor Yor Mor 1,2022-07-03
TH,Thailand,Pre-Market,CA,CIP,English or Thai,2022-07-03
TH,Thailand,Pre-Market,CA,Synopsis,Thai language,2022-07-03
TH,Thailand,Pre-Market,CA,IB (for not CE-mark MD),,2022-07-03
TH,Thailand,Pre-Market,CA,Patient information and ICF ,Thai language,2022-07-03
TH,Thailand,Pre-Market,CA,EC approval ,EC review must be submitted to the Thai FDA no later than 15 days after the authorized person receives this decision,2022-07-03
TH,Thailand,Pre-Market,CA,Power of attorney statement,"Foreign manufacturers have three possibilities to register their medical device in Thailand:
Set up a legal subsidiary entity
Appoint a local distributor
Appoint an independent third party",2022-07-03
TH,Thailand,Pre-Market,CA,"PI CV, GCP",,2022-07-03
TH,Thailand,Post-Market,CA,Cover Letter ,,2022-07-03
TH,Thailand,Post-Market,CA,Checklists and Attached Documents for Application Import License of the product. ,Document name: Nor Yor Mor 1,2022-07-03
TH,Thailand,Post-Market,CA,CIP,English or Thai,2022-07-03
TH,Thailand,Post-Market,CA,Synopsis,Thai language,2022-07-03
TH,Thailand,Post-Market,CA,IB (for not CE-mark MD),,2022-07-03
TH,Thailand,Post-Market,CA,Patient information and ICF ,Thai language,2022-07-03
TH,Thailand,Post-Market,CA,EC approval ,EC review must be submitted to the Thai FDA no later than 15 days after the authorized person receives this decision,2022-07-03
TH,Thailand,Post-Market,CA,Power of attorney statement,"Foreign manufacturers have three possibilities to register their medical device in Thailand:
Set up a legal subsidiary entity
Appoint a local distributor
Appoint an independent third party",2022-07-03
TH,Thailand,Post-Market,CA,"PI CV, GCP",,2022-07-03
VN,Viet Nam,Pre-Market,CA,Process same as EC,See EC submission for VN,2022-07-03
VN,Viet Nam,Post-Market,CA,Process same as EC,See EC submission for VN,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Cover Letter on headed paper,Addressed by Principal Investigator to Dubai Scientific research Ethics Committee),2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Application form,Download from webpage,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CIP & all curents admendments,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Synopsis ,in EN,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CRF,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,IB,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,PI have to obtain HOD signature,If multicenter study,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Approval from Head of Department and CEO of hospital,If study is conduct in Dubai Hospitals. contact Dubai Hospital Professional Development Office DHPDO@dha.gov.ae to know more.,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Approval is required to be obtained from Director of Primary health Care Centers,If Study is conducting at DHA Primary health Care Centers. Contact PHCC Professional Development Office.,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,CIP,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Synopsis,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Patient Information and Informed Consent,EN & ARABIC. Template available ,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,All Data collection Forms,"Patient diary, cards, questionnaires â€¦",2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Budget plan,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Financial Disclosure of Principal Investigator.,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Agreements between parties,to be digned by the PI,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,"PI CV, GCP",,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Proof of insurance ,,2022-07-03
AE,United Arab Emirates,Pre-Market,CA,Payment ,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Cover Letter on headed paper,Addressed by Principal Investigator to Dubai Scientific research Ethics Committee),2022-07-03
AE,United Arab Emirates,Post-Market,CA,Application form,Download from webpage,2022-07-03
AE,United Arab Emirates,Post-Market,CA,CIP & all curents admendments,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Synopsis ,in EN,2022-07-03
AE,United Arab Emirates,Post-Market,CA,CRF,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,IB,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,PI have to obtain HOD signature,If multicenter study,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Approval from Head of Department and CEO of hospital,If study is conduct in Dubai Hospitals. contact Dubai Hospital Professional Development Office DHPDO@dha.gov.ae to know more.,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Approval is required to be obtained from Director of Primary health Care Centers,If Study is conducting at DHA Primary health Care Centers. Contact PHCC Professional Development Office.,2022-07-03
AE,United Arab Emirates,Post-Market,CA,CIP,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Synopsis,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Patient Information and Informed Consent,EN & ARABIC. Template available ,2022-07-03
AE,United Arab Emirates,Post-Market,CA,All Data collection Forms,"Patient diary, cards, questionnaires â€¦",2022-07-03
AE,United Arab Emirates,Post-Market,CA,Budget plan,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Financial Disclosure of Principal Investigator.,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Agreements between parties,to be digned by the PI,2022-07-03
AE,United Arab Emirates,Post-Market,CA,"PI CV, GCP",,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Proof of insurance ,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,CE-mark certification,,2022-07-03
AE,United Arab Emirates,Post-Market,CA,Payment ,,2022-07-03
AU,Australia,Pre-Market,CA,Aplication Form ,www.hrea.gov.au,2022-07-03
AU,Australia,Pre-Market,CA,Protocol,,2022-07-03
AU,Australia,Pre-Market,CA,IB,,2022-07-03
AU,Australia,Pre-Market,CA,"PI CVs, GCPs",,2022-07-03
AU,Australia,Pre-Market,CA,Patient information & ICF,,2022-07-03
AU,Australia,Pre-Market,CA,Assent Form (if aplicable),,2022-07-03
AU,Australia,Pre-Market,CA,Recruitment Plan,,2022-07-03
AU,Australia,Pre-Market,CA,CRFs,,2022-07-03
AU,Australia,Pre-Market,CA,Data management plans,,2022-07-03
AU,Australia,Pre-Market,CA,Questionnaires,,2022-07-03
AU,Australia,Pre-Market,CA,Proof of insurance,,2022-07-03
AU,Australia,Post-Market,CA,Aplication Form ,www.hrea.gov.au,2022-07-03
AU,Australia,Post-Market,CA,Protocol,,2022-07-03
AU,Australia,Post-Market,CA,IB,,2022-07-03
AU,Australia,Post-Market,CA,"PI CVs, GCPs",,2022-07-03
AU,Australia,Post-Market,CA,Patient information & ICF,,2022-07-03
AU,Australia,Post-Market,CA,Assent Form (if aplicable),,2022-07-03
AU,Australia,Post-Market,CA,Recruitment Plan,,2022-07-03
AU,Australia,Post-Market,CA,CRFs,,2022-07-03
AU,Australia,Post-Market,CA,Data management plans,,2022-07-03
AU,Australia,Post-Market,CA,Questionnaires,,2022-07-03
AU,Australia,Post-Market,CA,Proof of insurance,,2022-07-03
CN,China,Pre-Market,CA,Cover Letter,Adapt to each RECs,2022-07-03
CN,China,Pre-Market,CA,Application for Human Research Ethics Review,,2022-07-03
CN,China,Pre-Market,CA,Protocol,,2022-07-03
CN,China,Pre-Market,CA,IB,,2022-07-03
CN,China,Pre-Market,CA,Patient information & ICF,,2022-07-03
CN,China,Pre-Market,CA,CRF,,2022-07-03
CN,China,Pre-Market,CA,"PI Cv, GCP",,2022-07-03
CN,China,Pre-Market,CA,NMPA approval letter,CA approval letter,2022-07-03
CN,China,Pre-Market,CA,Site sustainability,,2022-07-03
CN,China,Pre-Market,CA,Proof of insurance,,2022-07-03
CN,China,Pre-Market,CA,Sponsor statement ,,2022-07-03
CN,China,Post-Market,CA,Cover Letter,Adapt to each RECs,2022-07-03
CN,China,Post-Market,CA,Application for Human Research Ethics Review,,2022-07-03
CN,China,Post-Market,CA,Protocol,,2022-07-03
CN,China,Post-Market,CA,IB,,2022-07-03
CN,China,Post-Market,CA,Patient information & ICF,,2022-07-03
CN,China,Post-Market,CA,CRF,,2022-07-03
CN,China,Post-Market,CA,"PI Cv, GCP",,2022-07-03
CN,China,Post-Market,CA,NMPA approval letter,CA approval letter,2022-07-03
CN,China,Post-Market,CA,Site sustainability,,2022-07-03
CN,China,Post-Market,CA,Proof of insurance,,2022-07-03
CN,China,Post-Market,CA,Sponsor statement ,,2022-07-03
ID,Indonesia,Pre-Market,CA,Application Form,"Completely filled in using Indonesian and on the last page signed by the Principal Researcher, Supervisor/Coordinator",2022-07-03
ID,Indonesia,Pre-Market,CA,CIP,Complete from Cover to Bibliography. Don't forget to include version number on the cover,2022-07-03
ID,Indonesia,Pre-Market,CA,Patient information and ICF,Version on eachpage,2022-07-03
ID,Indonesia,Pre-Market,CA,Assent form if needed,,2022-07-03
ID,Indonesia,Pre-Market,CA,Application for ethical review (Cover Letter?),,2022-07-03
ID,Indonesia,Pre-Market,CA,Declaration of conflict of Interest,Mandatory for sponsor research ,2022-07-03
ID,Indonesia,Pre-Market,CA,"PI & team members Cv, GCP",Combined in 1 file ,2022-07-03
ID,Indonesia,Pre-Market,CA,List of all members in the center,,2022-07-03
ID,Indonesia,Pre-Market,CA,Proof of payment ,,2022-07-03
ID,Indonesia,Pre-Market,CA,Extra instruction (see notes),"File numbers 1 â€“ 5 are uploaded in PDF format (maximum 1 MB), not in format
JPG/JPEG images.
File numbers 6 â€“ 9 are uploaded in WORD/PDF format (maximum 1 MB), may not be in JPG/JPEG image format.
File numbers 10 â€“ 11 are uploaded in WORD/PDF/JPG/JPEG format",2022-07-03
ID,Indonesia,Post-Market,CA,Application Form,"Completely filled in using Indonesian and on the last page signed by the Principal Researcher, Supervisor/Coordinator",2022-07-03
ID,Indonesia,Post-Market,CA,CIP,Complete from Cover to Bibliography. Don't forget to include version number on the cover,2022-07-03
ID,Indonesia,Post-Market,CA,Patient information and ICF,Version on eachpage,2022-07-03
ID,Indonesia,Post-Market,CA,Assent form if needed,,2022-07-03
ID,Indonesia,Post-Market,CA,Application for ethical review (Cover Letter?),,2022-07-03
ID,Indonesia,Post-Market,CA,Declaration of conflict of Interest,Mandatory for sponsor research ,2022-07-03
ID,Indonesia,Post-Market,CA,"PI & team members Cv, GCP",Combined in 1 file ,2022-07-03
ID,Indonesia,Post-Market,CA,List of all members in the center,,2022-07-03
ID,Indonesia,Post-Market,CA,Proof of payment ,,2022-07-03
ID,Indonesia,Post-Market,CA,Extra instruction (see notes),"File numbers 1 â€“ 5 are uploaded in PDF format (maximum 1 MB), not in format
JPG/JPEG images.
File numbers 6 â€“ 9 are uploaded in WORD/PDF format (maximum 1 MB), may not be in JPG/JPEG image format.
File numbers 10 â€“ 11 are uploaded in WORD/PDF/JPG/JPEG format",2022-07-03
IN,India,Pre-Market,CA,Cover Letter,,2022-07-03
IN,India,Pre-Market,CA,Application Form,,2022-07-03
IN,India,Pre-Market,CA,CIP,,2022-07-03
IN,India,Pre-Market,CA,PI CV,Not more than 2 pages. Include no. of projects of PI,2022-07-03
IN,India,Pre-Market,CA,IB,,2022-07-03
IN,India,Pre-Market,CA,Statement that the study shall be done in accordance with ICMR and GCP guidelines,,2022-07-03
IN,India,Pre-Market,CA,IEC clearance of  other centers must be provided,Multicenters ,2022-07-03
IN,India,Pre-Market,CA,Budget plan,,2022-07-03
IN,India,Pre-Market,CA,Proof of insurance,,2022-07-03
IN,India,Pre-Market,CA,Recruiment plan,,2022-07-03
IN,India,Pre-Market,CA,Patient information and ICF,English/Hindi,2022-07-03
IN,India,Post-Market,CA,Cover Letter,,2022-07-03
IN,India,Post-Market,CA,Application Form,,2022-07-03
IN,India,Post-Market,CA,CIP,,2022-07-03
IN,India,Post-Market,CA,PI CV,Not more than 2 pages. Include no. of projects of PI,2022-07-03
IN,India,Post-Market,CA,IB,,2022-07-03
IN,India,Post-Market,CA,Statement that the study shall be done in accordance with ICMR and GCP guidelines,,2022-07-03
IN,India,Post-Market,CA,IEC clearance of  other centers must be provided,Multicenters ,2022-07-03
IN,India,Post-Market,CA,Budget plan,,2022-07-03
IN,India,Post-Market,CA,Proof of insurance,,2022-07-03
IN,India,Post-Market,CA,Recruiment plan,,2022-07-03
IN,India,Post-Market,CA,Patient information and ICF,English/Hindi,2022-07-03
JP,Japan,Pre-Market,CA,CIP,,2022-07-03
JP,Japan,Pre-Market,CA,Synopsis,Korean and English,2022-07-03
JP,Japan,Pre-Market,CA,Patient information and ICF,,2022-07-03
JP,Japan,Pre-Market,CA,Sample CRF,,2022-07-03
JP,Japan,Pre-Market,CA,Site sustainability,,2022-07-03
JP,Japan,Pre-Market,CA,Recruitment plan ,,2022-07-03
JP,Japan,Pre-Market,CA,Any compensation payment,,2022-07-03
JP,Japan,Pre-Market,CA,Proof of insurance,,2022-07-03
JP,Japan,Pre-Market,CA,"PI CV, GCP",,2022-07-03
JP,Japan,Pre-Market,CA,Contracts between sponsor/PI/CRO,,2022-07-03
JP,Japan,Post-Market,CA,CIP,,2022-07-03
JP,Japan,Post-Market,CA,Synopsis,Korean and English,2022-07-03
JP,Japan,Post-Market,CA,Patient information and ICF,,2022-07-03
JP,Japan,Post-Market,CA,Sample CRF,,2022-07-03
JP,Japan,Post-Market,CA,Site sustainability,,2022-07-03
JP,Japan,Post-Market,CA,Recruitment plan ,,2022-07-03
JP,Japan,Post-Market,CA,Any compensation payment,,2022-07-03
JP,Japan,Post-Market,CA,Proof of insurance,,2022-07-03
JP,Japan,Post-Market,CA,"PI CV, GCP",,2022-07-03
JP,Japan,Post-Market,CA,Contracts between sponsor/PI/CRO,,2022-07-03
KH,Cambodia,Pre-Market,CA,Name of the applicant with designation,,2022-07-03
KH,Cambodia,Pre-Market,CA,Name of the institute/Hospital/Field Area,,2022-07-03
KH,Cambodia,Pre-Market,CA,Aproval of the Director of the institution ,,2022-07-03
KH,Cambodia,Pre-Market,CA,Protocol,,2022-07-03
KH,Cambodia,Pre-Market,CA,Synopsis ,in Khmer & in English,2022-07-03
KH,Cambodia,Pre-Market,CA,Ethical issues ,,2022-07-03
KH,Cambodia,Pre-Market,CA,"Study Questionnaires, follow up, ..",in Khmer,2022-07-03
KH,Cambodia,Pre-Market,CA,Patient information and ICF,in Khmer,2022-07-03
KH,Cambodia,Pre-Market,CA,Pre-clinical animal data and clinical trial data from other countries,If applicable ,2022-07-03
KH,Cambodia,Pre-Market,CA,"PI CVs, GCPs, relevant publications during the last 5 years",,2022-07-03
KH,Cambodia,Pre-Market,CA,Relevant regulatory clearances and support,,2022-07-03
KH,Cambodia,Pre-Market,CA,Source of funding and financial requirements ,,2022-07-03
KH,Cambodia,Pre-Market,CA,An agreement to report any serious side effects or adverse drug reactions to NECHR,,2022-07-03
KH,Cambodia,Pre-Market,CA,Statement of conflicts of interest,,2022-07-03
KH,Cambodia,Pre-Market,CA,Fee ,,2022-07-03
KH,Cambodia,Post-Market,CA,Name of the applicant with designation,,2022-07-03
KH,Cambodia,Post-Market,CA,Name of the institute/Hospital/Field Area,,2022-07-03
KH,Cambodia,Post-Market,CA,Aproval of the Director of the institution ,,2022-07-03
KH,Cambodia,Post-Market,CA,Protocol,,2022-07-03
KH,Cambodia,Post-Market,CA,Synopsis ,in Khmer & in English,2022-07-03
KH,Cambodia,Post-Market,CA,Ethical issues ,,2022-07-03
KH,Cambodia,Post-Market,CA,"Study Questionnaires, follow up, ..",in Khmer,2022-07-03
KH,Cambodia,Post-Market,CA,Patient information and ICF,in Khmer,2022-07-03
KH,Cambodia,Post-Market,CA,Pre-clinical animal data and clinical trial data from other countries,If applicable ,2022-07-03
KH,Cambodia,Post-Market,CA,"PI CVs, GCPs, relevant publications during the last 5 years",,2022-07-03
KH,Cambodia,Post-Market,CA,Relevant regulatory clearances and support,,2022-07-03
KH,Cambodia,Post-Market,CA,Source of funding and financial requirements ,,2022-07-03
KH,Cambodia,Post-Market,CA,An agreement to report any serious side effects or adverse drug reactions to NECHR,,2022-07-03
KH,Cambodia,Post-Market,CA,Statement of conflicts of interest,,2022-07-03
KH,Cambodia,Post-Market,CA,Fee ,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Application Form,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,CIP,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Synopsis (Study outline form),,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,CRF,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Patient information & ICF,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Safety informtion ,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Conpensation/ Proof of insurance,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Recruiment plan,,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,"PI CV, GCP",Recent version,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Approvals from CA,If available ,2022-07-03
KR,Republic of  Korea,Pre-Market,CA,Expedited request form,in case of Expedited review,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Application Form,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,CIP,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Synopsis (Study outline form),,2022-07-03
KR,Republic of  Korea,Post-Market,CA,CRF,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Patient information & ICF,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Safety informtion ,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Conpensation/ Proof of insurance,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Recruiment plan,,2022-07-03
KR,Republic of  Korea,Post-Market,CA,"PI CV, GCP",Recent version,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Approvals from CA,If available ,2022-07-03
KR,Republic of  Korea,Post-Market,CA,Expedited request form,in case of Expedited review,2022-07-03
MY,Malaysia,Pre-Market,CA,IA-HOD-IA form,Required for all types of submission,2022-07-03
MY,Malaysia,Pre-Market,CA,PI CV GCP,All clinical trial study. GCP in Malaysian,2022-07-03
MY,Malaysia,Pre-Market,CA,Declaration of Conflict of Interest by PI,Required for all types of submission,2022-07-03
MY,Malaysia,Pre-Market,CA,Cover Letter,,2022-07-03
MY,Malaysia,Pre-Market,CA,Study Protocol,,2022-07-03
MY,Malaysia,Pre-Market,CA,IB,All interventional studies,2022-07-03
MY,Malaysia,Pre-Market,CA,Patient information & ICF,Compulsory to have English & Bahasa Malasian language. Optional: Chinese & Tamilâ€¦,2022-07-03
MY,Malaysia,Pre-Market,CA,"Assent Form+ Parental Information Sheet & Consent
Forms",If aplicable. Two separate assent forms for children aged 7-12 and 13-18 years old. Compulsory to have English & Bahasa Malasian language. Optional: Chinese & Tamilâ€¦,2022-07-03
MY,Malaysia,Pre-Market,CA,CRF/ Data Collection Form/Questionnaire,,2022-07-03
MY,Malaysia,Pre-Market,CA,Approval/exemption letter from MDA,"A document / letter containing the Medical Device Authorityâ€™s
registration / exemption for the device to be used in the
study.",2022-07-03
MY,Malaysia,Pre-Market,CA,Advertisement/ recruiment plan,,2022-07-03
MY,Malaysia,Pre-Market,CA,Proof of Insurance/ Letter of indemnity,,2022-07-03
MY,Malaysia,Pre-Market,CA,Memorandum of Understanding/ Research Agreement,,2022-07-03
MY,Malaysia,Post-Market,CA,IA-HOD-IA form,Required for all types of submission,2022-07-03
MY,Malaysia,Post-Market,CA,PI CV GCP,All clinical trial study. GCP in Malaysian,2022-07-03
MY,Malaysia,Post-Market,CA,Declaration of Conflict of Interest by PI,Required for all types of submission,2022-07-03
MY,Malaysia,Post-Market,CA,Cover Letter,,2022-07-03
MY,Malaysia,Post-Market,CA,Study Protocol,,2022-07-03
MY,Malaysia,Post-Market,CA,IB,All interventional studies,2022-07-03
MY,Malaysia,Post-Market,CA,Patient information & ICF,Compulsory to have English & Bahasa Malasian language. Optional: Chinese & Tamilâ€¦,2022-07-03
MY,Malaysia,Post-Market,CA,"Assent Form+ Parental Information Sheet & Consent
Forms",If aplicable. Two separate assent forms for children aged 7-12 and 13-18 years old. Compulsory to have English & Bahasa Malasian language. Optional: Chinese & Tamilâ€¦,2022-07-03
MY,Malaysia,Post-Market,CA,CRF/ Data Collection Form/Questionnaire,,2022-07-03
MY,Malaysia,Post-Market,CA,Approval/exemption letter from MDA,"A document / letter containing the Medical Device Authorityâ€™s
registration / exemption for the device to be used in the
study.",2022-07-03
MY,Malaysia,Post-Market,CA,Advertisement/ recruiment plan,,2022-07-03
MY,Malaysia,Post-Market,CA,Proof of Insurance/ Letter of indemnity,,2022-07-03
MY,Malaysia,Post-Market,CA,Memorandum of Understanding/ Research Agreement,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Study protocol,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Evidence of appropiate scientific peer review,Guidance: https://ethics.health.govt.nz/guides-templates-and-forms/scientific-peer-review-submissions-guidance/,2022-07-03
NZ,New Zealand,Pre-Market,CA,"PI CV, GCP",,2022-07-03
NZ,New Zealand,Pre-Market,CA,Patient information and ICF,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Assent Form ,If available,2022-07-03
NZ,New Zealand,Pre-Market,CA,Recruitment plan,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Surveys or questionnaires,,2022-07-03
NZ,New Zealand,Pre-Market,CA,Proof of Insurance,,2022-07-03
NZ,New Zealand,Post-Market,CA,Study protocol,,2022-07-03
NZ,New Zealand,Post-Market,CA,Evidence of appropiate scientific peer review,Guidance: https://ethics.health.govt.nz/guides-templates-and-forms/scientific-peer-review-submissions-guidance/,2022-07-03
NZ,New Zealand,Post-Market,CA,"PI CV, GCP",,2022-07-03
NZ,New Zealand,Post-Market,CA,Patient information and ICF,,2022-07-03
NZ,New Zealand,Post-Market,CA,Assent Form ,If available,2022-07-03
NZ,New Zealand,Post-Market,CA,Recruitment plan,,2022-07-03
NZ,New Zealand,Post-Market,CA,Surveys or questionnaires,,2022-07-03
NZ,New Zealand,Post-Market,CA,Proof of Insurance,,2022-07-03
PH,Philippines,Pre-Market,CA,"Find the right RECs and contact them directly. If No REC in the PHREB, Then apply to National EC: https://nec.pchrd.dost.gov.ph/index.php/requirementsforreview",Only level 3 PHREB Accredited RECs can review clinical trial studies. Webpage: https://ethics.healthresearch.ph/index.php/level-3-accredited-recs ,2022-07-03
PH,Philippines,Pre-Market,CA,Cover Letter,,2022-07-03
PH,Philippines,Pre-Market,CA,Application Form,,2022-07-03
PH,Philippines,Pre-Market,CA,Protocol,,2022-07-03
PH,Philippines,Pre-Market,CA,IB,,2022-07-03
PH,Philippines,Pre-Market,CA,Patient information and ICF,English & Tagalog version,2022-07-03
PH,Philippines,Pre-Market,CA,Subject Worksheets/Patient Diary /Alert Cards,English & Tagalog version,2022-07-03
PH,Philippines,Pre-Market,CA,Approval of the PFDA (Philippines CA),,2022-07-03
PH,Philippines,Pre-Market,CA,"PI CV, GCP",,2022-07-03
PH,Philippines,Pre-Market,CA,Site sustainability,,2022-07-03
PH,Philippines,Pre-Market,CA,Proof of insurance,,2022-07-03
PH,Philippines,Pre-Market,CA,Ethic Review Fee,,2022-07-03
PH,Philippines,Post-Market,CA,"Find the right RECs and contact them directly. If No REC in the PHREB, Then apply to National EC: https://nec.pchrd.dost.gov.ph/index.php/requirementsforreview",Only level 3 PHREB Accredited RECs can review clinical trial studies. Webpage: https://ethics.healthresearch.ph/index.php/level-3-accredited-recs ,2022-07-03
PH,Philippines,Post-Market,CA,Cover Letter,,2022-07-03
PH,Philippines,Post-Market,CA,Application Form,,2022-07-03
PH,Philippines,Post-Market,CA,Protocol,,2022-07-03
PH,Philippines,Post-Market,CA,IB,,2022-07-03
PH,Philippines,Post-Market,CA,Patient information and ICF,English & Tagalog version,2022-07-03
PH,Philippines,Post-Market,CA,Subject Worksheets/Patient Diary /Alert Cards,English & Tagalog version,2022-07-03
PH,Philippines,Post-Market,CA,Approval of the PFDA (Philippines CA),,2022-07-03
PH,Philippines,Post-Market,CA,"PI CV, GCP",,2022-07-03
PH,Philippines,Post-Market,CA,Site sustainability,,2022-07-03
PH,Philippines,Post-Market,CA,Proof of insurance,,2022-07-03
PH,Philippines,Post-Market,CA,Ethic Review Fee,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Cover Letter,State the list of document submission,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,CIP,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,IB,Arabic,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,GDPR ,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Patient recruiment,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Patient information & ICF,Arabic,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,CRF (all),,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Any compensation ,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Risks & benefits assessment,,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,"PI CV, GCP",,2022-07-03
SA,Saudi Arabia,Pre-Market,CA,Declaration of conflict of interestÂ ,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Cover Letter,State the list of document submission,2022-07-03
SA,Saudi Arabia,Post-Market,CA,CIP,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,IB,Arabic,2022-07-03
SA,Saudi Arabia,Post-Market,CA,GDPR ,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Patient recruiment,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Patient information & ICF,Arabic,2022-07-03
SA,Saudi Arabia,Post-Market,CA,CRF (all),,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Any compensation ,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Risks & benefits assessment,,2022-07-03
SA,Saudi Arabia,Post-Market,CA,"PI CV, GCP",,2022-07-03
SA,Saudi Arabia,Post-Market,CA,Declaration of conflict of interestÂ ,,2022-07-03
SG,Singapore,Pre-Market,CA,Application Form,ONLINE ishare/ROAM Download guidance. ,2022-07-03
SG,Singapore,Pre-Market,CA,CIP/Protocol,Template on webpage,2022-07-03
SG,Singapore,Pre-Market,CA,Patient information and ICF,English and local languagea,2022-07-03
SG,Singapore,Pre-Market,CA,PI CV GCP,,2022-07-03
SG,Singapore,Pre-Market,CA,Assent Form (if aplicable) ,,2022-07-03
SG,Singapore,Pre-Market,CA,Recruiment plan,"posters, brochures, advertisements, letter of invitation, scripts, etc",2022-07-03
SG,Singapore,Pre-Market,CA,CRF ,,2022-07-03
SG,Singapore,Pre-Market,CA,Please attach at least two relevant publications that support the conduct of the study.,Included in application Form,2022-07-03
SG,Singapore,Pre-Market,CA,IFU,If available,2022-07-03
SG,Singapore,Pre-Market,CA,Proof of insurance,Only for DSRB application,2022-07-03
SG,Singapore,Pre-Market,CA,DSMB Charter (if aplicale),https://ishare.singhealth.com.sg/,2022-07-03
SG,Singapore,Pre-Market,CA,ROAM platform,https://www.research.nhg.com.sg/sop/process/ROMP/Admin_Intranet_Login,2022-07-03
SG,Singapore,Post-Market,CA,Application Form,ONLINE ishare/ROAM Download guidance. ,2022-07-03
SG,Singapore,Post-Market,CA,CIP/Protocol,Template on webpage,2022-07-03
SG,Singapore,Post-Market,CA,Patient information and ICF,English and local languagea,2022-07-03
SG,Singapore,Post-Market,CA,PI CV GCP,,2022-07-03
SG,Singapore,Post-Market,CA,Assent Form (if aplicable) ,,2022-07-03
SG,Singapore,Post-Market,CA,Recruiment plan,"posters, brochures, advertisements, letter of invitation, scripts, etc",2022-07-03
SG,Singapore,Post-Market,CA,CRF ,,2022-07-03
SG,Singapore,Post-Market,CA,Please attach at least two relevant publications that support the conduct of the study.,Included in application Form,2022-07-03
SG,Singapore,Post-Market,CA,IFU,If available,2022-07-03
SG,Singapore,Post-Market,CA,Proof of insurance,Only for DSRB application,2022-07-03
SG,Singapore,Post-Market,CA,DSMB Charter (if aplicale),https://ishare.singhealth.com.sg/,2022-07-03
SG,Singapore,Post-Market,CA,ROAM platform,https://www.research.nhg.com.sg/sop/process/ROMP/Admin_Intranet_Login,2022-07-03
TH,Thailand,Pre-Market,CA,Books/notes for submitting research proposals,,2022-07-03
TH,Thailand,Pre-Market,CA,Proposal Form for Ethical Consideration For Biomedical Research Projects (AP 04-S04),,2022-07-03
TH,Thailand,Pre-Market,CA,Letter of approval from the first-class supervisor,Template: https://crec.submission-online.com/content/show?id=4 ,2022-07-03
TH,Thailand,Pre-Market,CA,CIP,,2022-07-03
TH,Thailand,Pre-Market,CA,Synopsis,in Thai language,2022-07-03
TH,Thailand,Pre-Market,CA,Patient information & ICF,,2022-07-03
TH,Thailand,Pre-Market,CA,CRF,,2022-07-03
TH,Thailand,Pre-Market,CA,IB ,AP 01-S07 Investigator's Brochure for Medical Device Study,2022-07-03
TH,Thailand,Pre-Market,CA,Recruiment plan and materials,,2022-07-03
TH,Thailand,Pre-Market,CA,Proof of insurance,,2022-07-03
TH,Thailand,Pre-Market,CA,Material transfer agreement (MTA),,2022-07-03
TH,Thailand,Pre-Market,CA,Research project budget,Draft version acceptable,2022-07-03
TH,Thailand,Pre-Market,CA,Conflict of Interest Form of the Principal Investigator and Co-Investigator,AP 06-S04 Conflict of Interest Form,2022-07-03
TH,Thailand,Pre-Market,CA,"PI CV, GCP",,2022-07-03
TH,Thailand,Pre-Market,CA,Proof of payment,,2022-07-03
TH,Thailand,Post-Market,CA,Books/notes for submitting research proposals,,2022-07-03
TH,Thailand,Post-Market,CA,Proposal Form for Ethical Consideration For Biomedical Research Projects (AP 04-S04),,2022-07-03
TH,Thailand,Post-Market,CA,Letter of approval from the first-class supervisor,Template: https://crec.submission-online.com/content/show?id=4 ,2022-07-03
TH,Thailand,Post-Market,CA,CIP,,2022-07-03
TH,Thailand,Post-Market,CA,Synopsis,in Thai language,2022-07-03
TH,Thailand,Post-Market,CA,Patient information & ICF,,2022-07-03
TH,Thailand,Post-Market,CA,CRF,,2022-07-03
TH,Thailand,Post-Market,CA,IB ,AP 01-S07 Investigator's Brochure for Medical Device Study,2022-07-03
TH,Thailand,Post-Market,CA,Recruiment plan and materials,,2022-07-03
TH,Thailand,Post-Market,CA,Proof of insurance,,2022-07-03
TH,Thailand,Post-Market,CA,Material transfer agreement (MTA),,2022-07-03
TH,Thailand,Post-Market,CA,Research project budget,Draft version acceptable,2022-07-03
TH,Thailand,Post-Market,CA,Conflict of Interest Form of the Principal Investigator and Co-Investigator,AP 06-S04 Conflict of Interest Form,2022-07-03
TH,Thailand,Post-Market,CA,"PI CV, GCP",,2022-07-03
TH,Thailand,Post-Market,CA,Proof of payment,,2022-07-03
VN,Viet Nam,Pre-Market,CA,Application form,signed and dated,2022-07-03
VN,Viet Nam,Pre-Market,CA,CIP,dated and version,2022-07-03
VN,Viet Nam,Pre-Market,CA,Synopsis,Vietnamese,2022-07-03
VN,Viet Nam,Pre-Market,CA,Description of ethics considerations,"GDPR, data management, compensation, etc",2022-07-03
VN,Viet Nam,Pre-Market,CA,IB,,2022-07-03
VN,Viet Nam,Pre-Market,CA,Patient information and ICF/Assent Form,,2022-07-03
VN,Viet Nam,Pre-Market,CA,Recruitment plan ,,2022-07-03
VN,Viet Nam,Pre-Market,CA,Data collection Forms,,2022-07-03
VN,Viet Nam,Pre-Market,CA,Other Ecs opinion (if available),,2022-07-03
VN,Viet Nam,Pre-Market,CA,"Procedure for monitoring, evaluating & managing Aes",,2022-07-03
VN,Viet Nam,Pre-Market,CA,Institution statement that allow the search to start,,2022-07-03
VN,Viet Nam,Pre-Market,CA,PI commitment to comply with ethical guidelines,,2022-07-03
VN,Viet Nam,Pre-Market,CA,"PI CV, GCP",,2022-07-03
VN,Viet Nam,Post-Market,CA,Application form,signed and dated,2022-07-03
VN,Viet Nam,Post-Market,CA,CIP,dated and version,2022-07-03
VN,Viet Nam,Post-Market,CA,Synopsis,Vietnamese,2022-07-03
VN,Viet Nam,Post-Market,CA,Description of ethics considerations,"GDPR, data management, compensation, etc",2022-07-03
VN,Viet Nam,Post-Market,CA,IB,,2022-07-03
VN,Viet Nam,Post-Market,CA,Patient information and ICF/Assent Form,,2022-07-03
VN,Viet Nam,Post-Market,CA,Recruitment plan ,,2022-07-03
VN,Viet Nam,Post-Market,CA,Data collection Forms,,2022-07-03
VN,Viet Nam,Post-Market,CA,Other Ecs opinion (if available),,2022-07-03
VN,Viet Nam,Post-Market,CA,"Procedure for monitoring, evaluating & managing Aes",,2022-07-03
VN,Viet Nam,Post-Market,CA,Institution statement that allow the search to start,,2022-07-03
VN,Viet Nam,Post-Market,CA,PI commitment to comply with ethical guidelines,,2022-07-03
VN,Viet Nam,Post-Market,CA,"PI CV, GCP",,2022-07-03
